

Does Pfizer Need a Low Cost Low Volume Manufacturing Option?

Jeff Salm, Thomas Crowley, Tanya Shang, Anthony Barry and Kristin Murray, Pfizer, Inc, Andover, MA

A Low Cost, Low Volume (LCLV) approach to clinical manufacturing has previously been proposed^{1,2}. The goal of this approach was to provide Pfizer research organizations with an option for initiating first-in-human studies in the clinic for a reduced initial investment.